Biovitrum and Syntonix Dose First Hemophilia B Patient in Clinical Trial of a Novel Factor IXFc Treatment

Stockholm, Sweden  and  Waltham, MA  -  May 27,  2008.  Biovitrum  AB
(STO:BVT)  and  Syntonix  Pharmaceuticals,  Inc.,  a  subsidiary   of
Biogen/Idec (NASDAQ: BIIB) today announced the initiation of a  phase
I/IIa open-label, dose escalation study of a long-acting, recombinant
Factor IXFc (FIXFc) protein in patients with hemophilia B. The  study
is ongoing  at clinics  in  the United  States  and will  assess  the
safety, tolerability  and pharmacokinetics  of  Factor IXFc  in  this
patient population.

This FIXFc compound, which pre-clinical studies have shown to have an
extended  half-life,  could  enable  effective  treatment  with  less
frequent injections  for both  prophylaxis and  on-demand therapy  in
hemophilia B. The current global market for Factor IX products is USD
600 million per year."We are excited about developing  FIXFc together with Syntonix  since
hemophilia is  a prioritized  therapeutic  and business  area  within
Biovitrum. In addition, we are developing a recombinant Factor VIIIFc
hemophilia product with Syntonix. Both  these programs fit well  with
Biovitrum's long experience  and broad knowledge  within the area  of
protein therapeutics and our specialist care business strategy." said
Martin Nicklasson, CEO of Biovitrum."We are pleased to  have moved the FIXFc  program, which is based  on
our SynFusionTM technology,  into clinical studies.   The purpose  of
both the FIXFc and Factor VIIIFc programs is to improve the lives  of
hemophilia patients and  their families," said  Matt Ottmer,  General
Manager of Syntonix.

About Hemophilia
Hemophilia is  a rare  hereditary disorder  in which  the ability  of
patients' blood to clot is impaired. As a result, the patient suffers
from excessive bleeding and  uncontrolled internal bleeding,  leading
to pain  and eventual  permanent damage  to joints  and muscles.  One
form, Hemophilia B results from mutations that impair the  production
of Factor IX. It has been reported that even with "proper  treatment"
the life expectancy  of hemophilia  patients is about  10 years  less
than for  individuals without  hemophilia. Increasingly,  the  normal
mode of treatment for younger patients is a prophylaxis regimen where
patients are infused two or three times per week to maintain a better
circulating  level   of  coagulation   factor.  Long   term   studies
demonstrate that  such  regimens  greatly  reduce  if  not  eliminate
progressive joint deterioration.

About SynFusionTM Technology
The SynFusion technology is based on Syntonix's proprietary Fc-fusion
technologies to create  longer-acting biopharmaceuticals.  Well-known
and  validated   traditional  Fc-fusion   drugs,  such   as   Enbrel®
(etanercept) for the  treatment of rheumatoid  arthritis, consist  of
two copies  of a  biopharmaceutical linked  to the  Fc region  of  an
antibody to  improve  pharmacokinetics,  solubility,  and  production
efficiency.  SynFusion drugs consist of a novel Fc-fusion  construct,
called a monomer that links only a single copy of the drug to the  Fc
region  on   an  antibody   to  optimize   the  pharmacokinetic   and
pharmacodynamic properties of the biopharmaceutical when compared  to
traditional Fc-fusion constructs

About Biovitrum
Biovitrum is a  specialty pharmaceutical company  with operations  in
Sweden and  in  the  UK.  Biovitrum markets  a  range  of  specialist
pharmaceuticals primarily in the Nordic countries. The company has  a
research portfolio with several projects in clinical and  preclinical
phases for a number of well defined specialist indications. Biovitrum
has the expertise and experience to take its projects all the way  to
the market. Biovitrum develops  and produces protein-based drugs  and
also  has  small  molecule   research  expertise  and   capabilities.
Biovitrum has revenues  of approximately SEK  1.2 billion and  around
500 employees. Biovitrum's share is listed on the OMX Nordic Exchange
in Stockholm. For more information see www.biovitrum.com.

About Syntonix
Syntonix Pharmaceuticals, Inc. (Waltham,  MA, USA) is a  wholly-owned
subsidiary of  Biogen Idec.  Syntonix is  developing next  generation
biopharmaceuticals that enable better treatment options for  patients
with devastating chronic diseases  such as hemophilia and  autoimmune
disorders. The  company  applies  its core  technologies  to  develop
long-acting biopharmaceuticals that may be injected less  frequently,
and to discover novel drugs to treat antibody-mediated autoimmune and
inflammatory  disorders.   The  resulting   proteins,  peptides   and
antibodies are  being  commercialized  through  internal  development
programs and  collaborations  with biotechnology  and  pharmaceutical
partners. More information is available at http://www.syntnx.com/.



For more information please contact:

Biovitrum AB (publ)
Erik Kinnman, Vice President Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

Martin Nicklasson, CEO
Phone. +46 8 697 20 00
martin.nicklasson@biovitrum.com